Thu, Apr 17, 2014, 3:21 AM EDT - U.S. Markets open in 6 hrs 9 mins

Recent

% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

  • dooper55 dooper55 Sep 8, 2012 10:25 PM Flag

    Favorable HDSA comments re PDE10

    The Huntington's Disease Society of America published comments about OMER's PDE10 IND application.

    Their comments, which preceded a reprint of OMER's news release, had this to say:

    "IND application filed for a Phase I Clinical Trial of a PDE10 inhibitor

    In the Press Release below, we learn that Omeros has filed an IND for a Phase I clinical trial for its PDE10 inhibitor. This is good news for the HD community since preclinical data, which we reported last year, shows that it might be helpful for HD patients, treating both the disease and its symptoms.

    For example, in one study, R6/2 mice were treated with a PDE10A inhibitor from 4 weeks of age until they were euthanized at 13 weeks. Both neuropathology and symptoms were ameliorated. Cell loss in the cortex and the striatum was reduced, there were fewer intranuclear aggregates in the striatal neurons, and the degree of microglia activation was decreased. Behavioral symptoms such as rotarod performance were also improved over untreated mice.

    We will keep reporting information about the proposed trial as we receive it.

    - Marsha L. Miller, Ph.D., September 6, 2012"

 
OMER
11.33+0.01(+0.09%)Apr 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.